• FuseBio’s ROR1 cell engager demonstrated superior cytotoxicity and safety profile compared to conventional and second generation cell engagers
   

• Potential for improved efficacy in solid tumors with reduced risk of adverse events including cytokine release syndrome and tumor lysis syndrome
   

• Strong efficacy was observed with PD1-F18 in multiple aggressive animal tumor models including a complete response (CR) rate ranging from 60%-100% without weight loss or other signs/symptoms of toxicity

 

​

WOBURN, Mass. – November 11, 2022 – Fuse Biotherapeutics, Inc., a biotechnology company specializing in innovative immunotherapies for cancer and autoimmunity, today announced the presentation of new data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held on November 8-12, 2022, in Boston, MA.

The poster presentation, entitled "A ROR1 specific CD3 bispecific T-cell engager engineered for solid tumors with an expanded therapeutic window" (Poster Number: 1068), highlighted Fuse Biotherapeutics' advancements in protein engineering that facilitate the development of next generation cell engagers designed to optimize both anti-tumor activity and safety.

“We have put together a world class team of protein engineers and immunologists that developed a technology platform for merging the potency of first generation cell engagers like Blincyto with the safety of second generation cell engagers that generally sacrifice efficacy for safety,” said Jeffrey Takimoto, Ph.D, Chief Executive Officer of Fuse Biotherapeutics. Brian Rabinovich, Ph.D, Chief Scientific Officer of Fuse Biotherapeutics, further commented; “Our cell engager platform, which is built upon the premise of working in concert with natural immunological pathways that have evolved to irradicate danger without damaging healthy tissues is being applied to our growing pipeline of immune-therapeutics designed to augment and preserve the intrinsic pathways that have evolved to protect humans from cancer, infectious disease and autoimmunity”.

​

​

Details regarding the upcoming SITC abstract presentation:
 

November 11, 2022, 11:55 AM - 1:25 PM EST

​

Poster 1068: A ROR1 specific CD3 bispecific T-cell engager engineered for solid tumors with an expanded therapeutic window

​

Abstract Highlights: As an example of a next generation cell engager, FuseBio engineered a ROR1 specific cell engager with properties that increased the size of its therapeutic window that can be dosed to achieve equivalent tumor specific killing as first generation T cell engagers that cause severe systemic toxicity without adverse events yet retaining the capacity to dose into pro-inflammatory cytokine release that is critical to eliminating solid tumors. The cell engager uses a platform technology that optimizes the distance between immune cell and tumor cell to maximize killing within a dose dependent “window” of pro-inflammatory cytokine release. The ROR1 T cell engager generated (1) decouples cytotoxicity from cytokine release and (2) facilitates the discrimination between ROR1 cell surface density on normal versus tumor cells. The final drug candidate provides a superior therapeutic index with reduced risks of CRS and TLS, the capacity to dose higher, avoid continuous infusion and potentially mediate better efficacy in solid tumors.

​

The abstract will be made available for viewing on FuseBio’s website upon presentation at the SITC 2022 Annual Meeting (www.fusebiotx.com).

​

​

About Fuse Biotherapeutics, Inc.
 

Fuse Biotherapeutics is a biotechnology company dedicated to developing next-generation immunotherapies for cancer. Leveraging cutting-edge technologies and a deep understanding of the immune system, Fuse Biotherapeutics is committed to transforming the treatment landscape and improving patient outcomes.

​

​

Contact:
bd@fusebiotx.com